Boston Scientific Corporation Announces Board and Committee Changes

Boston Scientific Corporation announced February 23, 2026, the election of Catherine R. Smith and Christophe P. Weber to its Board of Directors, effective February 18, 2026. Smith is a seasoned executive with deep expertise in finance, corporate strategy and operational excellence. She currently serves as chief financial officer of Starbucks.

Previously, she held chief financial officer roles at Nordstrom, Bright Health, Target, Express Scripts and Walmart, supporting large, complex organizations through periods of significant growth. Smith currently serves on the board of PPG Industries. She holds an MBA from the University of Southern California and a bachelor's degree in business economics from the University of California, Santa Barbara.

Weber brings extensive global leadership experience across the pharmaceutical industry. He is the president and chief executive officer of Takeda Pharmaceutical since April 2015, retiring in June 2026. He joined Takeda in 2014 as president and chief operating officer.

Prior to Takeda, Weber held roles of increasing responsibility in multiple countries at GlaxoSmithKline. He has led large-scale transformations grounded in the principles of patient and customer-centricity, helping global organizations operate more effectively while remaining focused on delivering meaningful outcomes for patients. Weber earned a doctorate in pharmacy from Université de Lyon and has an advanced degree in accounting and finance.

The election of Smith and Weber to Boston Scientific's Board of Directors follows the previously announced retirements of John Sununu from the board, who will serve until, and will not stand for re-election at, Boston Scientific's 2026 annual meeting of stockholders. The Board further appointed Ms. Smith to serve as a member of the Audit Committee and the Nominating and Governance Committee of the Board, and Mr. Weber to serve as a member of the Executive Compensation and Human Resources Committee and the Risk, Science and Technology Committee of the Board, in each case, effective as of February 23, 2026.